These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 12173711)

  • 1. Neutropenic colitis after treatment of acute myelogenous leukemia with idarubicin and cytosine arabinoside.
    Hogan WJ; Letendre L; Litzow MR; Tefferi A; Hoagland HC; Pruthi RK; Kaufmann SH
    Mayo Clin Proc; 2002 Aug; 77(8):760-2. PubMed ID: 12173711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enterocolitis as initial presentation of acute myelogenous leukemia exacerbated by induction chemotherapy with idarubicin-cytosine arabinoside.
    Wood RA
    Mayo Clin Proc; 2002 Oct; 77(10):1133. PubMed ID: 12374257
    [No Abstract]   [Full Text] [Related]  

  • 3. Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial).
    Willemze R; Suciu S; Muus P; Halkes CJ; Meloni G; Meert L; Karrasch M; Rapion J; Vignetti M; Amadori S; de Witte T; Marie JP
    Ann Hematol; 2014 Jun; 93(6):965-75. PubMed ID: 24682421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia].
    Liu Y; Ke XY; Ma J; Shen ZX; Zhang XH; Du X; Zhao YM; Lv JQ; Zhan ZM; Zeng XY; Xu XH; Lu ZS
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):706-8. PubMed ID: 17274381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase-three trial comparing daunorubicin or idarubicin combined with cytosine arabinoside in acute myelogenous leukemia.
    Vogler WR; Velez-Garcia E; Omura G; Raney M
    Semin Oncol; 1989 Feb; 16(1 Suppl 2):21-4. PubMed ID: 2648581
    [No Abstract]   [Full Text] [Related]  

  • 6. Oral idarubicin plus cytosine arabinoside in the treatment of acute non lymphoblastic leukemia in elderly patients.
    Pagano L; Sica S; Marra R; Voso MT; Storti S; Di Mario A; Leone G
    Haematologica; 1991; 76(6):517-8. PubMed ID: 1820991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Early phase II study of Idarubicin combined with cytarabine in acute myelogenous leukemia. Idarubicin Study Group].
    Ogawa M; Masaoka T; Yamada K; Kimura K
    Gan To Kagaku Ryoho; 1993 May; 20(7):907-14. PubMed ID: 8489297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.
    Giles FJ; Kantarjian HM; Cortes JE; Faderl S; Verstovsek S; Thomas D; Garcia-Manero G; Wierda W; Ferrajoli A; Kornblau S; Mattiuzzi GN; Tsimberidou AM; Albitar M; O'Brien SM; Estey E
    Leuk Res; 2005 Jun; 29(6):649-52. PubMed ID: 15863204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
    Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.
    Reiffers J; Huguet F; Stoppa AM; Molina L; Marit G; Attal M; Gastaut JA; Michallet M; Lepeu G; Broustet A; Pris J; Maraninchi D; Hollard D; Fabères C; Mercier M; Hurteloup P; Danel P; Tellier Z; Berthaud P
    Leukemia; 1996 Mar; 10(3):389-95. PubMed ID: 8642852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction chemotherapy with idarubicin plus N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute myelogenous leukemia: a newly designed induction regimen--a prospective, cooperative multicenter study.
    Park HS; Kim DW; Kim CC; Kim HK; Kim JS; Hwang TJ; Kim HJ; Kim HS; Song HS; Park JW; Ahn HS; Chung TJ; Cho KS; Lee KS; Choi YM
    Semin Hematol; 1996 Oct; 33(4 Suppl 3):24-9. PubMed ID: 8916313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idarubicin combined with intermediate-dose cytosine arabinoside in the treatment of refractory acute leukemia.
    Leone G; Pagano L; Marra R; Di Pietro N; Storti S; Sica S; D'Onofrio G; Ganzina F
    Haematologica; 1989; 74(1):57-61. PubMed ID: 2498185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similar incidence of typhlitis in patients receiving various doses of daunorubicin or idarubicin as induction for acute myeloid leukemia.
    Seddon AN; Chaim J; Akin O; Drill E; Michael AG; Adel N; Tallman MS
    Leuk Res; 2018 May; 68():48-50. PubMed ID: 29544131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The results of treatment with idarubicin in childhood acute nonlymphoblastic leukemia.
    Saşmaz I; Tanyeli A; Bayram I; Antmen B; Yilmaz L; Küçükosmanoğlu O; Kilinç Y
    Turk J Pediatr; 2004; 46(1):32-7. PubMed ID: 15074372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective randomized trial of KRN8602 and cytosine arabinoside vs. daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. The KRN8602 Leukemia Study Group.
    Takemoto Y; Sampi K; Kuraishi Y; Okabe K; Tamura K; Mizoguchi H; Saito H; Masaoka T; Ogawa M
    Int J Hematol; 1999 Jul; 70(1):20-5. PubMed ID: 10446490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction therapy of newly diagnosed acute nonlymphocytic leukemia with idarubicin and cytosine arabinoside--the Taiwan experience.
    Chen YC; Lin SF; Yao M; Chen TY; Tsao CJ; Chen TP
    Semin Hematol; 1996 Oct; 33(4 Suppl 3):30-4. PubMed ID: 8916314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idarubicin plus continuous-infusion high-dose cytarabine as treatment for patients with acute myelogenous leukemia or myelodysplastic syndrome.
    Estey EH; Kantarjian H; Keating M
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):1-5. PubMed ID: 8290966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful fetal outcome after exposure to idarubicin and cytosine-arabinoside during the second trimester of pregnancy--a case report.
    Claahsen HL; Semmekrot BA; van Dongen PW; Mattijssen V
    Am J Perinatol; 1998 May; 15(5):295-7. PubMed ID: 9643634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Acute myeloid leukemia with poor prognosis: treatment with oral 4-demethoxydaunorubicin (idarubicin) and low-dose cytarabine via subcutaneous route].
    Helg C; Chapuis B; Grob JP; Pugin P
    Schweiz Med Wochenschr; 1990 Apr; 120(15):548-52. PubMed ID: 2336558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience.
    Pastore D; Specchia G; Carluccio P; Liso A; Mestice A; Rizzi R; Greco G; Buquicchio C; Liso V
    Ann Hematol; 2003 Apr; 82(4):231-5. PubMed ID: 12707726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.